Use of .DELTA.5 androstenes in the treatment of HIV wasting syndrome
US5885977A · kind A · utility
5Cited by
2References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 15, 1997 |
| Grant date | Mar 23, 1999 |
| Priority date | — |
| Expiry date | Jan 15, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/5685
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
HIV-related weight loss, HIV-related cachexia and HIV-related wasting syndrome can be treated by administering therapeutic amounts of the steroid .DELTA.5-androstene-3.beta.-ol-7,17 dione and metabolizable precursors thereof, such as .DELTA.5-androstene-3.beta.-acetoxy-7,17 dione, which are readily metabolized in vivo to .DELTA.5 androstene-3.beta.-ol-7,17 dione. Such treatment can be prophylactic, modulatory, ameliorative or curative in nature.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.